期刊文献+

多柔比星心脏毒性防治策略研究进展 被引量:3

Preventive and therapeutic strategies of doxorubicin cardiotoxicity:research advances
下载PDF
导出
摘要 多柔比星(DOX)的临床应用受到潜在的致命心脏毒性的限制。增强DOX的抗癌作用同时减少相关的心脏毒性一直是近年来研究的热点。目前可能的方法包括使用心脏保护药物、DOX衍生物以及改变给药方式。本文结合近年来的研究进展提出防治DOX心脏毒性的新思路,试图找到既能发挥抗癌功效、又能起到心脏保护作用的靶点和药物。 The utilization of doxorubicin(DOX)is compromised by potential lethal cardiotoxicity in clinical application.Improving DOX efficacy in cancer cells while minimizing DOX-associated cardiotoxicity is in the forefront of research. Available methods at present include cardioprotective agents,DOX derivates and dosage schedules. This paper proposes new ideas on potential drug targets aiming at enhancing cancer therapy and cardioprotection simultaneously.
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2015年第5期574-580,共7页 Journal of International Pharmaceutical Research
基金 国家自然科学基金资助项目(81100080)
关键词 多柔比星 抗肿瘤化疗 心脏毒素类 临床治疗方案 doxorubicin cancer chemotherapy cardiotoxic agents treatment protocols
  • 相关文献

参考文献66

  • 1Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect[J]. Curr Med Chem, 2009, 16(25):3267-3285.
  • 2Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials[J]. BMC Cancer, 2010, 10:337. doi:10.1186/1471-2407-10-337.
  • 3Rochette L, Guenancia C, Gudjoncik A, et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms[J]. Trends Pharmacol Sci, 2015, 36(6): 326-348.
  • 4Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18(11):1639-1642.
  • 5Dirks-Naylor AJ. The role of autophagy in doxorubicin-induced cardiotoxicity[J]. Life Sci, 2013, 93(24):913-916.
  • 6Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis[J]. Eur J Cancer, 2013, 49(13):2900-2909.
  • 7Salazar-Mendiguchia J, Gonzalez-Costello J, Roca J, et al. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist[J]. Arch Cardiol Mex, 2014, 84(3):218-223.
  • 8Marty M, Espie M, Llombart A, et al. Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy[J]. Ann Oncol, 2006, 17(4):614-622.
  • 9Lebrecht D, Geist A, Ketelsen UP, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats[J]. Br J Pharmacol, 2007, 151(6):771-778.
  • 10Sterba M, Popelova O, Vavrova A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection[J]. Antioxid Redox Signal, 2013, 18(8):899-929.

二级参考文献15

  • 1江泽飞,宋三泰.蒽环类化疗药物治疗乳腺癌的新动向[J].中华肿瘤杂志,2005,27(4):193-195. 被引量:27
  • 2徐兵河,赵龙妹,王佳玉,袁芃.泰索帝联合顺铂治疗31例蒽环类耐药性晚期乳腺癌疗效分析[J].中华肿瘤杂志,2006,28(6):471-473. 被引量:46
  • 3Jemal A,Siegel R,Ward E. Cancer statistics,2008[J].CA:A Cancer Journal for Clinicians,2008.71-96.
  • 4Barry E,Alvarez JA,Scully RE. Anthracycline-induced cardiotoxicty:course,pathophysiology,prevention and management[J].Expert Opinion on Pharmacotherapy,2007.1039-1058.
  • 5Lipshultz SE,Alvarez JA,Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer[J].Heart,2008.525-533.
  • 6Marty M,Espié M,Llombart A. Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline based chemotherapy[J].Annals of Oncology,2006.614-622.
  • 7van Dalen EC,Caron HN,Dickinson HO. Cardioprotective interventions for cancer patients receiving anthracyclines[J].Cochrane Database of Systematic Reviews,2011.CD003917.
  • 8Mwale F,Ciobanu I,Demers CN. Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats[J].Calcified Tissue International,2005.175-179.
  • 9Khasraw M,Bell R,Dang C. Epirubicin:is it like doxombicin in breast cancer. A clinical review[J].Breast,2012.142-149.
  • 10Montaigne D,Hurt C,Neviere R. Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies[J].Biochem Res Int,2012.951539.

共引文献28

同被引文献23

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部